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Objectives: The relationship between resource utilisation and patient phenotype 
in type 2 diabetes (T2D) is not well characterised. This study aimed to assess fac-
tors associated with weight gain (WG) and the occurrence of hypoglycaemia in 
T2D patients managed with metformin plus sulfonylurea (M+S) and any associated 
impact upon hospital resource utilisation. MethOds: The study was a retrospec-
tive cohort study using the UK Clinical Practice Research Datalink (CPRD) and the 
Hospital Episode Statistics (HES) database. The association between phenotypic 
factors at baseline (therapy escalation from metformin to M+S) with WG (> 2kg 
weight change over 12 months) and presence of any recorded hypoglycaemia over 
12 months following therapy escalation was assessed using logistic regression. 
Hospitalisation associated with increasing body mass index (BMI) and hypoglycae-
mia was also assessed. Results: A total of 11,071 patients met the study inclusion/
exclusion criteria. WG was observed in 28.35% of patients and was significantly 
associated with baseline age (OR= 0.99), female gender (OR= 0.87), baseline weight 
(OR= 1.003) and HbA1c (OR= 1.06). Hypoglycaemia occurred in 1.3% of patients and 
was significantly associated with duration of diabetes (OR= 1.04), baseline HbA1c 
(OR= 0.86) and prior complications status (OR= 1.92). Hospitalisation occurred in 10% 
of patients and was significantly associated with BMI (OR= 1.02) but not hypoglycae-
mia. The mean number of hospital admissions over the follow-up period was 1.7, 1.8, 
1.9 and 3.1 in those with BMIs at the time of admission in the normal, overweight, 
obese and morbidly obese categories respectively. cOnclusiOns: This real-world 
observational analysis suggests there are identifiable phenotypic characteristics 
predictive of WG and hypoglycaemia. This study also shows a general relationship 
between increasing BMI and hospitalisation that may not be adequately captured 
in widely used vascular risk equations such as UKPDS in which BMI has minimal 
influence on risk. Consequently, the value of diabetes management strategies that 
minimise WG may be underestimated.
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Objectives: Frequency of self-monitoring of blood glucose (SMBG) varies in 
patients with type 2 diabetes mellitus (T2DM) and there is debate as to the true 
benefit it plays in the management of the condition. The aim of this study was to 
compare the frequency of SMBG using patient medication record (PMR) dispensed 
data, with self-reported data, and to assess the relationship between type of glu-
cose-lowering therapy to SMBG frequency among patients with T2DM dispensed 
glucose test strips. MethOds: Patients with T2DM were identified in community-
pharmacies (n= 116) using PMRs in 2012. Patients who consented to participation 
were surveyed in a face-to-face interview where self-reported (SR) frequency 
of SMBG was determined. Dispensed data were classified by the mechanism of 
action of the blood glucose lowering regimen, (secretagogues vs. sensitisers). Test 
strip use over a 12 month period was calculated and compared to SR use from 
the patient survey. Analysis was performed in MS Excel® and SAS®. Results: 
Data from 484 patients were analysed (mean age 65yrs). Sensitising agents alone 
accounted for 45% of the cohort, secretagogues alone - 8%, a combination of both 
- 42%, and diet 5%. Approximately 52% of patients reported frequency of SMBG as 
once or twice daily vs 56% in the dispensed data. 13% of patients reported a fre-
quency of at least 3 times daily vs 21% for PMR data. There was no statistically sig-
nificant difference in SR frequency among those on the various glucose-lowering 
regimens. No correlations were found between frequency of use and age, gender, 
place of residence or number of prescribed medicines. cOnclusiOns: Results 
from this study highlight (i) differences in frequency of blood glucose monitoring 
between dispensed data and SR data and (ii) the difficulty in accurately capturing 
this type of data. A reliance on either type of data alone may be insufficient to 
accurately inform decision making.
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Objectives: Hypoglycaemia is common in diabetic patients, often as a side effect 
of a treatment. Its occurrence can influence patients’ professional life and gener-
ate extra direct costs to the health care system. Severe (requiring another person’s 
assistance) hypoglycaemic events (SHEs), especially leading to hospitalisation, are 
associated with the highest burden and for that reason their real frequency and 
costs should be calculated properly. The aim of the study was to assess the accuracy 
of reporting of hypoglycaemia to the National Health Fund in Poland. MethOds: 
A combination of prospective and retrospective designs was applied. A detailed 
retrospective analysis of 117 hospitalised patients’ case histories was performed 
from the period of February-March 2013. In addition, prospectively, in March and 
April 2013, 45 patients were interviewed and their clinical records were analysed. 
Information was collected in special case report forms. Real hospitalisation costs 
were also calculated. Results: In the retrospective arm hypoglycaemia affected 42 
patients (55% of type 1 and 25% of type 2) and 85 SHEs were recorded. Only 2 patients 
were reported in the hypoglycaemia DRG group compared to a broader diabetes/
hyperglycaemia DRG group, where the financing level is higher. A financial differ-
ence equal to 7,082 EUR was generated due to more favourable classification of these 
cases. In the prospective arm 20 patients experienced hypoglycaemia, whereas only 
one was coded as hypoglycaemic. It has generated 2,247 EUR difference. Even with 
this financially more favourable, (still clinically justified but less precise) coding 
hypoglycaemic patients generated losses equal to 23,628 EUR in retrospective and 
5,053 EUR in prospective group. cOnclusiOns: Our study provided a direct proof 
association with the probability of seeing an endocrinologist: rates of specialist 
visits are the largest under the age of 25 (p< 0.05). In addition, people treated with 
insulin and those with another endocrine disorder are more likely to see a special-
ist (p< 0.001). In contrast, the newly diagnosed and patients followed by a general 
practitioner (GP) present lower probabilities of specialist visits (p< 0.001). Moreover, 
the probability of specialist visit rises when the density of endocrinologists is large 
in the patients’ neighbourhood, while it decreases with the distance (in kilome-
tres) from the patients’ house to the endocrinologist’s office. Finally, the chances 
of seeing a specialist increase with income and decrease as the cost for a visit 
rises. cOnclusiOns: Our results are consistent with previous literature showing 
evidence of the existence of a substitution effect between GPs and specialists in 
diabetes care. We show that financial barriers exist even in a population of patients 
receiving national health insurance coverage.
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Objectives: Severe hypoglycemic events (SHE) contribute to health care utiliza-
tion for insulin-dependent diabetics, and may drive expenditures by health care 
payers. Rescue treatment for SHE includes glucagon kits, which are administered 
by caregivers and difficult to use. Consequently, there are high rates of unsuccess-
ful administration, leading to increased health care service use. A new kit under 
development aims to ease the burden of administration by reducing the complex-
ity. The new device aims to increase successful use and lower rates of health care 
service utilization. This study aimed to understand payers’ receptivity to this value 
proposition. MethOds: Seven medical directors from US payers were interviewed, 
representing commercial, Medicare, Medicaid and other covered lives. The interview 
was designed to understand plans’ focus on diabetes and hypoglycemia, cover-
age/reimbursement of current kits, and impressions of characteristics of the new 
kit. Results: The prevention of SHE is not a concern for insurers; the risk of SHE 
is largely a type 1 problem, representing a small subset of their overall diabetic 
population. While payers are confident in current kits’ effectiveness, they are not 
focused on managing access to such a low-volume treatment. Current kits are cov-
ered by insurers without restrictions, and contracting is not prevalent due to low 
volume. Payers believe the new kit will be an improvement over current kits, but do 
not believe it will reduce the cost of SHE. cOnclusiOns: Payers feel that the new 
kit will be an improvement over currently available kits, but are skeptical that the 
ease of use will translate into lower health care service use. Additionally, SHE is not 
a major cost driver among their diabetic population; therefore, SHE is not a high-
priority condition. Consequently, for optimal market access and reimbursement, the 
new kit must demonstrate significant reductions in high-cost health care utilization 
(e.g., ED, hospitalizations) to justify a premium price without coverage restrictions.
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Objectives: The primary objective was to assess the impact of using ‘metformin 
plus sulphonylureas’ (Met+SU) in comparison with ‘metformin plus other oral 
anti-hyperglycaemic agents’ (Met+OHA) in patients with Type 2 Diabetes (T2D) 
on diabetes-associated secondary health care utilisation in the UK. The second-
ary objectives included investigating individual components of the primary objec-
tive. MethOds: This retrospective cohort study used data from the Clinical Practice 
Research Datalink (CPRD) linked to Hospital Episodes Statistics. Adults (≥ 40 years) 
with T2D initiated on dual therapy with Met+SU or Met+OHA following metformin 
monotherapy were identified during the period April 2003–March 2012 and com-
prised the two study cohorts. Propensity scores were estimated and Met+SU patients 
caliper matched to Met+OHA patients to balance the covariates (including HbA1C 
and duration of diabetes at baseline). Diabetes-associated secondary health care 
utilisation (inpatient admissions and outpatient visits) were measured from > 6 
months post-initiation of dual therapy until treatment change or end of follow-up. 
Outcomes were calculated as rate ratios (RR), adjusted for over dispersion using 
negative binomial regression and propensity score for covariates. Results: 14,416 
patients in total were identified and in the directly matched analysis, 1,704 patients 
were included in each cohort. For the primary objective, the Met+SU cohort had a 
numerically higher rate of diabetes-related secondary health care utilisation than 
Met+OHAs (adjusted RR 1.12, 95% confidence interval [95%CI]: 0.97-1.29). For the 
secondary endpoints examining individual components, the adjusted RR for Met+SU 
cohort for inpatient admissions was 1.34 (95%CI 0.92–1.96) and 1.10 (95%CI 0.95-1.28) 
for outpatient visits. Macrovascular complications, accounting for 68.7% of inpa-
tient admissions, occurred at a significantly higher rate in the Met+SU cohort than 
Met+OHA (adjusted RR 1.77, 95%CI: 1.15-2.71). cOnclusiOns: Glucose-lowering 
combination therapy with metformin plus sulphonylurea is associated with a direc-
tionally higher rate of secondary health care utilisation than metformin plus other 
oral anti-hyperglycaemic agents.
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patients were more likely to have annual cholesterol test, smoking status assessed, 
eye and renal function screening than normal weight patients. However, the over-
weight and obese class I/II patients were less likely to achieve optimal HbA1c (7% 
or less) and BP (< 130/80 mmHg) than normal BMI patients. The AdjOR for achieving 
optimal HbA1c decreased from 0.88 (95%CI 0.86-0.91) for overweight to 0.77 (0.72-
0.83) for obese class II; and BP decreased from 0.74 (0.99-1.05) for overweight to 0.48 
(0.45-0.52) for obesity class II. More obese class II and III patients had optimal LDL-
cholesterol control compared to normal BMI patients, AdjOR 1.11 (1.03-1.19) and 
1.16 (1.04-1.29) respectively. cOnclusiOns: Overweight and obese patients with 
diabetes were less likely to achieve the optimal HbA1c and BP control than normal 
BMI patients. Clinicians can identify the patients with higher BMI and poor risk 
factor control for more intense intervention to improve diabetes care and outcomes.
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Objectives: Investigating and comparing the sources of prevalence data used in 
German drug reimbursement dossiers within the AMNOG-framework in order to 
explore causes for deviating prevalence estimates. MethOds: All publicly avail-
able dossiers on diabetes mellitus type II were retrieved from the Federal Joint 
Committee’s homepage (http://www.g-ba.de). We investigated the epidemiological 
sources in the dossiers on their representativity (i. e., population-level epidemiologi-
cal data), actuality (year of data collection), method of data collection, data quality, 
and open access. Results: As of early June 2014, 13 dossiers were published on 
diabetes mellitus type II. Overall, 23 different sources for quantifying the preva-
lence were used, which can be grouped into 5 categories: clinical trials, registries, 
health insurances’ claims data, commercial data-providers, and a governmental 
data-provider. Data was mostly collected 5 or more years ago (except for the com-
mercial and governmental data-providers). Data was retrieved by means of physi-
cians’ statements; patient surveys with voluntary disclosure; diagnostic tests (such 
as the oral glucose tolerance test); national registries; secondary data from health 
insurances, and (raw) secondary data of pharmacy prescriptions with physician 
diagnoses. Besides differences in diagnostic criteria, reasons for deviation among 
sources include: the sample size and making adjustments to improve representativ-
ity for Germany; the chosen approach to analyze secondary data; differentiation of 
type II from type I diabetes mellitus, and (not) considering undiagnosed or untreated 
cases. While accessing the data of publications and of the commercial providers 
requires a payment, health insurance data is not freely available in Germany (yet). 
The governmental data-provider is accessible without restrictions and free of 
charge. cOnclusiOns: The need for accurate population-level data and access to 
it is highlighted by the present case-study. Sources for prevalence data in diabetes 
mellitus type II were characterized by a variety of differences in the methods applied 
to derive (the) data, leading to deviating estimates.
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Objectives: Published studies have shown that lifestyle intervention in adults 
with prediabetes can improve health outcomes and reduce or delay onset of type 
2 diabetes. Improved health translates to lower medical costs, reduced mortality, 
and higher levels of employment and productivity. This study examined patient 
characteristics that help predict future medical expenditures avoided and economic 
benefits to society associated with lifestyle intervention. MethOds: A Markov-
based microsimulation model utilizing Monte Carlo simulation was constructed to 
simulate patient health and economic outcomes over ten years with and without 
a lifestyle intervention. The population examined was a nationally representative 
sample (n= 2,887) of US adults with prediabetes from the 2003-2010 National Health 
and Nutrition Examination Survey who meet the American Diabetes Association’s 
screening criteria for diabetes. Prediction equations for diabetes and sequelae, medi-
cal expenditures, economic outcomes, mortality, and quality of life came from the 
published trials and studies, such as the UK Prospective Diabetes Study. The analy-
sis simulated body weight and hemoglobin A1c benefits reported in the 10-year 
follow-up results from the lifestyle arm of the Diabetes Prevention Program and 
Outcomes Study (DPPOS). OLS regression was subsequently used to analyze the 
initial patient characteristics and their relation to subsequent outcomes. Results: 
Simulated outcomes suggest that age, sex, race, obese status, and HbA1c at time 
of intervention are strong predictors of successful economic outcomes (medical 
expenditures and societal benefit). Intervention impact on medical savings generally 
increased with age through age 65, while total economic benefits of the interven-
tion increase through age 60. Women had $4,200 in higher medical savings then 
men. Obese participants had $3,000 higher medical savings than non-obese par-
ticipants. cOnclusiOns: The expected economic benefit of lifestyle intervention 
varies systematically by patient characteristics. Patients age 55-64 experienced the 
most medical savings, while patients age 45-54 experienced the largest societal 
economic impact.
PDB170
efficacy of The aUToMaTeD TaRgeT glUcose conTRol: a sysTeMaTic 
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Objectives: Tight glucose control in critically ill patients is difficult and labor 
intensive, resulting in poor efficacy of glycemic control and increased hypoglyce-
mia rate. The purpose of this study was to evaluate the safety and effectiveness 
of the automated target glucose control using computer-based insulin algo-
of underreporting of hypoglycaemia in clinical hospital settings in Poland caused 
by DRG- based financing standards. There is a need of reflecting real treatment cost 
in the level of reimbursement in this group of patients.
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Objectives: Diabetes Mellitus affects approximately 60 million Europeans, with 
prevalence increasing. Diabetes is associated with a number of severe comorbidi-
ties, including visual impairment, lower extremity conditions/amputation, neu-
ropathy, renal disease and cardiovascular disease. Managing underlying disease 
can significantly improve disease outcomes, though adherence remains a challenge. 
With the major expansion of consumer technology-based health care solutions and 
European initiatives like the REACTION project, diabetic patients are more involved 
in care than ever before. Our study looks at patient centric drivers of adherence to 
technology based diabetes self-management in Europe. MethOds: An in-depth 
analysis of current European initiatives implementing digital health management 
solutions was performed, as well as overall demographic and statistical research 
of the European diabetes population. Additionally, using dual data collection meth-
ods, involving telephone-based interviews and internet-based questionnaires, a 
total of 2,307 diabetes patients in the US were sampled. Questions focused on 
demographic, lifestyle, treatment, access to information, and socioeconomic sta-
tus. Data from US diabetic patient preferences related to digital health solutions 
and patient engagement strategies were reviewed in the context of diabetes self-
management solutions being deployed in Europe. Results: Socioeconomic disad-
vantage amongst European citizens has been shown to significantly contribute to 
development of diabetes and related complications. Among our study population, 
diabetics with a lower socioeconomic status and the elderly showed drastically 
lower rates of access to internet at home or at work (58.1% and 66.3%, respectively), 
as compared to those who were employed with an average income > $60,000 (92.2%). 
This same group preferred to get information from their health care providers ver-
sus the internet. cOnclusiOns: While programs are being developed to impact 
diabetic treatment adherence via IT based diabetes self-management solutions, 
patient characteristics and preferences need to be understood to optimize impact. 
Additional research is required to understand the best methods to reach these 
at-risk populations.
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Objectives: In Ukraine, 1.2 million people have diabetes mellitus (DM). 80 insu-
lins and 169 oral hypoglycemic preparations are registered. However, incomplete 
information on DM patients results in problems with providing their medicines. 
To develop a computer information retrieval system (CIS) for the registration of 
patients with DM and their pharmacotherapy (including financing sources) and 
to optimize the requirements for medicines; the CIS can be used to analyse the 
pharmaceutical care of patients with DM. MethOds: This study includes designin 
a CIS, entering pharmacotherapy information of DM patients, and use of the CIS 
to analyze the quality of pharmaceutical care of DM patients. Results: The study 
was conducted at the Ternopil Region, Ukraine. The study was based in 2 hospitals, 
2 dispensaries, and 12 pharmacies and examined the public and private sectors. 
The CIS was developed for use at national level and contains information on 
individual pharmacotherapy (27 insulins, 46 oral hypoglycemic preparations) of 
2,186 patients (282 DM type I). The CIS consists of 4 blocks: “Patient” (935 men, 
1261 women; from them 12 child) “Pharmacotherapy” (371 - insulin therapy, 1727 - 
oral hypoglycemic agents) and “Financing sources” blocks contain information on 
the centralized and local budgets, funds on maintenance of people that suffered 
from the Chernobyl accident, humanitarian help, and self-financing. The 4th block 
contains information on interactions of medicines. The analyses of individuals’ 
pharmacotherapies has shown that the CIS is an effective tool and can support 
endocrinologists in monitoring consumption of medicines by each patient. The 
system also provides expert analyses of changes of schemes, doses of medicines, 
and financing sources for individual patients. cOnclusiOns: The CIS provides 
the doctor with the ability to precisely define what medicines are necessary for 
the patient, define availability of medicines, and raise rationality and safety of 
use of antidiabetic medicines.
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Objectives: The study aimed to examine the disparity of risk factor screening and 
clinical outcomes depending on bodyweight of patients with diabetes mellitus at 9 
National Healthcare Group (NHG) Polyclinics in Singapore. MethOds: Data were 
extracted from NHG Diabetes Registry. Diabetes care bundle measures of 8 process 
indicators (biannual blood pressure (BP), bodyweight and HbA1c test measurement, 
annual serum cholesterol level, smoking, eye, foot and nephropathy assessment) 
and 3 intermediate outcome indicators (HbA1c ≤ 7%, BP < 130/80 mmHg and LDL-C 
< 2.6mmol/L) were measured. Rates of these indicators were compared by BMI 
according to WHO classification. Multivariate logistic regression for achieving the 
individual indicators was referenced to the normal BMI group. Results: In 2012, 
87,552 patients were enrolled for diabetes care at 9 NHG Polyclinics. Mean age was 
64.1± 11.6. 51.8% were female. 70.6% were Chinese. 40.4% were overweight and 20.8% 
were obese. After adjusting for age, gender and ethnicity, overweight and obese 
